Phase 3 Clinical Trials With Primary Completion Dates in April 2017

This is a list of Phase 3 trials with primary completion dates in April 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ARGS Argos Therapeutics, Inc. 2017-04-01 Phase 3 NCT01582672 Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
BIVV Bioverativ Inc. 2017-04-01 Phase 3 NCT02502149 Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
CBPO China Biologic Products, Inc. 2017-04-01 Phase 3 NCT01979900 Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis
CEMP Cempra, Inc. 2017-04-01 Phase 3 NCT02210325 Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea
CPHI China Pharma Holdings, Inc. 2017-04-01 Phase 3 NCT01979900 Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis
NOVN Novan, Inc. 2017-04-01 Phase 3 NCT02672332 P3 Study in Acne Comparing Once Daily SB204 and Vehicle
NOVN Novan, Inc. 2017-04-01 Phase 3 NCT02667444 P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne
VRX Valeant Pharmaceuticals International, Inc. 2017-04-01 Phase 3 NCT02786901 LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery